Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Iontophoretic Transport of Donepezil Hydrochloride through Skin: Flux Enhancement by Chemical Enhancer and Iontophoresis

  • Received : 2011.11.18
  • Accepted : 2011.12.06
  • Published : 2011.12.20
Download PDF
⟨ Previous Next ⟩

Abstract

The objective of this work is to investigate the effect of chemical enhancer and current on the flux of donepezil hydrochloride (DH) through skin. Ethanol and N-methyl pyrrolidone (NMP) were used as chemical enhancers in combination with iontophoresis. We also have studied the effect of pH on flux and evaluated the role of electroosmosis. In vitro flux study was performed at $33^{\circ}C$, using side-by-side diffusion cell and full thickness hairless mouse skin. Passive flux of DH without enhancer was very small. As the concentration of enhancer increased, passive flux increased. After current application, flux increased markedly and the time to reach maximum decreased. Without enhancer, maximum flux was about 50 fold larger than that obtained without current. These results indicate that electromigration is playing a major role for the transport. As the enhancer concentration increased, flux also increased. NMP and ethanol increased not only the passive delivery, but also the iontophoretic delivery. Flux results indicate that ethanol has better ability than NMP in enhancing the transport of DH. The magnitudes of increase in flux by these enhancers indicate that there is a large synergistic effect in flux enhancement. Flux results from pH study showed that electroosmotic flow is reversed at low pH and the flux is hindered. These results provided some information on the flux enhancing ability of ethanol and NMP in combination with iontophoresis. The data also provided some mechanistic insights into the role of electromigration and electroosmosis on flux through skin.

Keywords

References

  1. Jhoo, J.H., Kim, K.W., Huh, Y., Lee, S.B., Park, J.H., Lee, J.J., Choi, E.A., Han, C., Choo, I.H., Youn, J.C., Lee, D.Y., Woo, J.I., 2008. Prevalence of dementia and its subtypes in an elderly urban korean population: results from the Korean Longitudinal Study on Health And Aging (KLoSHA). Dement. Geriatr. Cogn. Disord. 26(3), 270-276.
  2. Brookmeyer, R., Johnson, E., Ziegler-Graham, K., Arrighi, H.M., 2007. Forecasting the global burden of Alzheimer's disease. Alzheimers. Dement. 3(3), 186-191. https://doi.org/10.1016/j.jalz.2007.04.381
  3. England, E., 2006. Improving the management of dementia. BMJ. 332, 681-682. https://doi.org/10.1136/bmj.332.7543.681
  4. Querfurth, H.W., LaFerla, F.M., 2010. Alzheimer's disease. N. Engl. J. Med. 362(4), 329-344. https://doi.org/10.1056/NEJMra0909142
  5. Scarpini, E., Scheltens, P., Feldman, H., 2003. Treatment of Alzheimer's disease: current status and new perspectives. Lancet. Neurol. 2, 539-547. https://doi.org/10.1016/S1474-4422(03)00502-7
  6. Francis, P.T., Palmer, A.M., Snape, M., Wilcock, G.K., 1999. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry. 66(2), 137-47. https://doi.org/10.1136/jnnp.66.2.137
  7. Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., Ashe, K.H., 2006. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 440, 352-357. https://doi.org/10.1038/nature04533
  8. Zhao, C., Deng, W., Gage, F.H., 2008. Mechanisms and functional implications of adult neurogenesis. Cell. 132(4), 645-660.
  9. Jann, M.W., Shirley, K.L., Small, G.W., 2002. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet. 41, 719-739. https://doi.org/10.2165/00003088-200241100-00003
  10. Lleo, A., Greenberg, S.M., Growdon , J.H., 2006. Current pharmacotherapy for Alzheimer's disease. Annu. Rev. Med. 57, 513-533. https://doi.org/10.1146/annurev.med.57.121304.131442
  11. Cummings, J., Winblad, B., 2007. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Rev. Neurother. 7(11), 1457-1463. https://doi.org/10.1586/14737175.7.11.1457
  12. Olivares, D., Deshpande, V.K., Shi, Y., Lahiri, D.K., Greig, N.H., Rogers, J.T., Huang, X., 2011. N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer's Disease, Vascular Dementia and Parkinson's Disease. Curr. Alzheimer Res. Aug 30.
  13. Tariot, P.N., Farlow, M.R., Grossberg, G.T., Graham, S.M., McDonald, S., Gergel, I., 2004. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized placebo controlled trial. Journal of the American Medical Association. 291, 317-324. https://doi.org/10.1001/jama.291.3.317
  14. Nakano, S., Asada , T., Matsuda, H., Uno, M., Takasaki, M., 2001. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J. Nuclear. Med., 42(10), 1441-1445
  15. Tiseo, P. J., Perdomo, C. A., Friedhoff, L. T., 1998. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single- dose study. Br. J. Clin. Pharmacol. 46(S1), 19-24.
  16. Physician's Desk Reference. 53th ed, 1999. Medical Economics Company, Montvale, NJ, pp. 2364-2367.
  17. Crismon, M.L., 1998. Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease. Pharmacotherapy. 18(2), 47-54.
  18. Kishnani, P.S., Sullivan, J.A., Walter, B.K., Spiridigliozzi, G.A., Doraiswamy, P.M., Krishnan, K.R., 1999. Cholinergic therapy for Down's syndrome. Lancet. 353(9158), 1064-1065. https://doi.org/10.1016/S0140-6736(98)05285-4
  19. Rogers, S.L., Friedhoff, L.T., 1996. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia. 7(6), 293-303.
  20. Subedi, R. K., Oh, S. Y., Chun, M. K., Choi, H. K., 2010. Recent advances in transdermal drug delivery. Arch. Pharm. Res. 33(3), 339-351. https://doi.org/10.1007/s12272-010-0301-7
  21. Winblad, B., Cummings, J., Andreasen, N., Grossberg , G., Onofrj, M., Sadowsky, C., Zechner, S., Nagel, J., Lane, R., 2007. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's diseaserivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry. 22(5), 456- 467. https://doi.org/10.1002/gps.1788
  22. FDA Issues Complete Response Letter for $Aricept^{{\circledR}}$ Patch (donepezil transdermal system), http://www.health.netsimpler.com/ fda-issues-complete-response-letter-for-aricept%C2%AE-patchdonepezil- transdermal-system/, April 25, 2011.
  23. Yan, G., Li, S.K., Higuchi, W.I., 2005. Evaluation of constant current alternating current iontophoresis for transdermal drug delivery. J. Control Release. 110(1), 141-150., https://doi.org/10.1016/j.jconrel.2005.09.006
  24. Leboulanger, B., Guy, R. H., Delgado-Charro, M. B., 2004. Reverse iontophoresis for non-invasive transdermal monitoring. Physiol. Meas. 25(3), R35-R50. https://doi.org/10.1088/0967-3334/25/3/R01
  25. Oda, Y., Ohe, H., Asakawa, N., Yoshida, Y., Sato, T., 1992. Resolution of 1-benzyl-4-[(5, 6-dimethoxy-1-indanon)-2-yl] methylpiperidine hydrochloride enantiomers in plasma by highperformance liquid chromatography with direct injection into avidin-conjugated column. J. Liq. Chromatogr. 15, 2997-3012. https://doi.org/10.1080/10826079208016366
  26. Choi, Y.R., Oh, S. Y., 2010. Electrotransport of Donepezil Hydrochloride from Poly(ethylene oxide) Hydrogel. J. Kor. Pharm. Sci. 40(2), 91-100. https://doi.org/10.4333/KPS.2010.40.2.091
  27. Avdeef, A., 2007. Solubility of sparingly-soluble ionizable drugs. Adv. Drug. Deliv. Rev. 59, 568-590. https://doi.org/10.1016/j.addr.2007.05.008
  28. Ahad, A., Aqil, M., Kohli, K., Chaudhary, H., Sultana, Y., Mujeeb, M., Talegaonkar, S., 2009. Chemical penetration enhancers: a patent review. Expert Opin. Ther. Pat. 19(7), 969-988. https://doi.org/10.1517/13543770902989983
  29. Koizumi, A., Fujii, M., Kondoh , M., Watanabe, Y., 2004. Effect of N-methyl-2-pyrrolidone on skin permeation of estradiol. Eur. J. Pharmaceutics. 57(3), 473-478.
  30. Barry, B.W., 1987. Mode of action of penetration enhancers in human skin. J. Controlled Rel. 6(1), 85-97. https://doi.org/10.1016/0168-3659(87)90066-6
  31. Williams, A.C., Barry, B.W., 2004. Advanced Drug Delivery Reviews. 56, 603-618. https://doi.org/10.1016/j.addr.2003.10.025
  32. Pershing, L.K., Lambert, L.D., Knutson, K., 1990. Mechanism of ethanol-enhanced estradiol permeation across human skin in vivo. Pharm. Res. 7, 170-175. https://doi.org/10.1023/A:1015832903398
  33. Yum,S.I., 1994. Permeation enhancement with ethanol. In: drug permeation enhancement. Marcel Dekker. New York.
  34. Megrab, N.A., Williams, A.C., Barry, B.W., 1995. Oestradiol permeation across human skin, silastic and snake skin membranes: the effects of ethanol/water co-solvent systems. Int. J. Pharm. 116, 101-112. https://doi.org/10.1016/0378-5173(94)00321-U
  35. Heit, M. C., Riviere, J. E., 1997. Electrically-Assisted transdermal drug delivery. Pharmceutical Research. 14(6), 687-761. https://doi.org/10.1023/A:1012129801406
  36. Merino, V., Lopez, A., Kalia, Y.N., Guy, R.H., 1999. Electrorepulsion versus electroosmosis : effect of pH on the iontophoresis flux of 5-fluorouracil. Pharm. Res. 16(5), 758-761. https://doi.org/10.1023/A:1018841111922
  37. Bommannan, B., Potts, R.O., Guy, R., 1991. Examination of the effect of ethanol on human stratum corneum in vivo using infrared spectroscopy. J. Controlled Release. 16(3), 299-304. https://doi.org/10.1016/0168-3659(91)90006-Y
  38. Hirvonen, J., Guy, R.H., 1998. Transdermal iontophoresis: modulation of electroosmosis by polypeptides. J. Controlled Release. 50(1-3), 283-289. https://doi.org/10.1016/S0168-3659(97)00150-8
  39. Hirvonen, J., Guy, R.H., 1997. Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances. Pharm. Res. 14, 1258-1263. https://doi.org/10.1023/A:1012127512251
  40. Oh, S.Y., 2004. Transdermal delivery of ketoprofen and the effect of electroosmosis. J. Kor. Pharm. Sci. 34(6), 491-497. https://doi.org/10.4333/KPS.2004.34.6.491
  41. Sieg, A., Guy, R.H., Delgado-Charro, M.B., 2004. Noninvasive glucose monitoring by reverse iontophoresis in vivo: application of the internal standard concept. Clin. Chem. 50(8), 1383-1390. https://doi.org/10.1373/clinchem.2004.032862
  42. Bath, B.D., White, H.S., Scott, E.R., 2000. Visualization and analysis of electroosmotic flow in hairless mouse skin. Pharm. Res. 17, 471-475. https://doi.org/10.1023/A:1007589306661
  43. Marro, D., Guy, R.H., Delgado-Charro, M.B., 2001. Characterization of the iontophoretic permselectivity properties of human and pig skin. J. Contr. Rel. 70, 213-217. https://doi.org/10.1016/S0168-3659(00)00350-3